 CAMBRIDGE, Mass., July 09, 2021 GLOBE NEWSWIRE -- Foghorn Therapeutics Inc. Nasdaq: FHTX, a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15. 